XML 17 R9.htm IDEA: XBRL DOCUMENT v3.26.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2026
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

The following table describes contracts, instructions or written plans for the sale or purchase of our securities adopted by our directors and certain officers during the three months ended March 31, 2026, each of which is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c), referred to as Rule 10b5-1 trading plans.

 

Name

Action Taken

Nature of Trading Arrangement

Duration of Trading Arrangement

Aggregate Number of Securities

Paul Peter Tak, M.D., Ph.D., FMedSci (Chief Executive Officer, President and Director)

Adoption (March 13, 2026)

Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c)

Earlier of (i) June 30, 2027 and (ii) the completed sale of the maximum aggregate number of securities under the plan

Up to 880,245 shares

Charles Schoch (Chief Financial Officer, Treasurer and Secretary)

Adoption (March 13, 2026)

Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c)

Earlier of (i) June 30, 2028 and (ii) the completed sale of the maximum aggregate number of securities under the plan

Up to 38,038 shares

Francesca Barone, M.D., Ph.D. (Chief Scientific Officer)

Adoption (March 16, 2026)

Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c)

Earlier of (i) June 30, 2028 and (ii) the completed sale of the maximum aggregate number of securities under the plan

Up to 93,789 shares

W. Garrett Nichols, M.D., M.S. (Chief Medical Officer)

Adoption (March 16, 2026)

Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c)

Earlier of (i) November 1, 2027 and (ii) the completed sale of the maximum aggregate number of securities under the plan

Up to 52,493 shares

Seshu Tyagarajan, Ph.D., RAC (Chief Technical and Development Director)

Adoption (March 16, 2026)

Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c)

Earlier of (i) March 31, 2028 and (ii) the completed sale of the maximum aggregate number of securities under the plan

Up to 128,564 shares

 

No other directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the three months ended March 31, 2026.
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Rule 10b51 Arr Modified Flag false
Non Rule 10b51 Arr Modified Flag false
Paul Peter Tak  
Trading Arrangements, by Individual  
Name Paul Peter Tak
Title Chief Executive Officer, President and Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 13, 2026
Expiration Date June 30, 2027
Aggregate Available 880,245
Charles Schoch  
Trading Arrangements, by Individual  
Name Charles Schoch
Title Chief Financial Officer, Treasurer and Secretary
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 13, 2026
Expiration Date June 30, 2028
Aggregate Available 38,038
Francesca Barone  
Trading Arrangements, by Individual  
Name Francesca Barone
Title Chief Scientific Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 16, 2026
Expiration Date June 30, 2028
Aggregate Available 93,789
W. Garrett Nichols  
Trading Arrangements, by Individual  
Name W. Garrett Nichols
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 16, 2026
Expiration Date November 1, 2027
Aggregate Available 52,493
Seshu Tyagarajan  
Trading Arrangements, by Individual  
Name Seshu Tyagarajan
Title Chief Technical and Development Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 16, 2026
Expiration Date March 31, 2028
Aggregate Available 128,564